Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The 8th International Workshop on CAR-T and Bispecifics (iwCAR-T) took place in Tampa, FL, on April 24-26, 2026, bringing together leading clinical researchers to discuss the latest advances in CAR therapies and bispecific antibodies. iwCAR-T 2026 was supported by Genentech (Platinum), BMS (Gold), A2 Bio (Gold), Johnson&Johnson (Gold), Autolus (Silver), Caribou Biosciences (Silver), Galapagos (Silver), Immatics (Silver), Iovance Biotherapeutics (Silver), Kite (Silver), Legend Biotech (Silver), Lyell (Silver), Miltenyi Biomedicine (Silver), and Novartis (Silver). Supporters have no influence over the production of the content.
iwCAR-T 2026
The 8th International Workshop on CAR-T and bispecifics
24–26 April 2026 | Tampa, FL
The 8th International Workshop on CAR-T and Bispecifics (iwCAR-T) took place in Tampa, FL, on April 24-26, 2026, bringing together leading clinical researchers to discuss the latest advances in CAR therapies and bispecific antibodies. iwCAR-T 2026 was supported by Genentech (Platinum), BMS (Gold), A2 Bio (Gold), Johnson&Johnson (Gold), Autolus (Silver), Caribou Biosciences (Silver), Galapagos (Silver), Immatics (Silver), Iovance Biotherapeutics (Silver), Kite (Silver), Legend Biotech (Silver), Lyell (Silver), Miltenyi Biomedicine (Silver), and Novartis (Silver). Supporters have no influence over the production of the content.
Explore roundtable discussions
View all videos
Keynote: targeting non-canonical tumor-specific antigens with engineered T cells
Patrick Hwu Moffitt Cancer Center, Tampa, FL, United States
CARs for neurological autoimmune diseases & autoimmune rheumatic disorders
Current CAR-T trials in lupus – current data and future potential
Vikas Majithia Mayo Clinic in Florida, Jacksonville, FL, United States
Autologous CD19-CAR T in SLE, SSc and IIM - data from the CASTLE-trial
Melanie Hagen University Hospital Erlangen, Erlangen, Germany
CAR T-cell therapy in MS: Latest results with miv-cel (KYV-101)
Jeffrey Dunn Stanford Medicine, Palo Alto, CA, United States
CAR T-cell therapy in autoimmune neuromuscular diseases: translational insights from miv-cel (KYV-101) in myasthenia gravis, immune-mediated neuropathies, and stiff-person spectrum disorders
Jeremias Motte Ruhr University Bochum, Bochum, Germany
New frontiers, new challenges: CARs for neurological autoimmune diseases
Matt Lunning University of Nebraska Medical Center, Omaha, NB, United States
BCMA-directed mRNA CAR T-cell therapy for myasthenia gravis
Tuan Vu University of South Florida, Tampa, FL, United States
T-cell engagers and CARs in CLL
Liso-cel in CLL/SLL
Tanya Siddiqi City of Hope, Duarte, CA, United States
Novel T-cell engagers for CLL/NHL:AZD5492
Mazyar Shadman Fred Hutchinson Cancer Research Center, Seattle, WA, United States
TBC
Mechanisms of resistance to CAR T-cell therapy in CLL
Michael Bishop University of Chicago Medical Center, Chicago, IL, United States
The future of therapeutics in Richter’s transformation: CAR-T vs. bispecifics or small molecules
Alexey Danilov City of Hope, Duarte, CA, United States
T-cell engagers and CARs in ALL
New generation of CD19-bispecifics in ALL
Ibrahim Aldoss City of Hope, Duarte, CA, United States
CAR T in B-ALL, now what?
Bijal Shah Moffitt Cancer Center, Tampa, FL, United States
TBC
T-cell engagers and CARs in myeloid malignancies
SENTI-202: A logically gated off-the-shelf cell therapy for AML
Stephen Strickland SCRI at TriStar Bone Marrow Transplant, Nashville, TN, United States
TBC
CLN-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in relapsed/refractory AML and MDS
Maher Abdul-Hay NYU Langone, New York City, NY, United States
Augmenting memory-like NK cells to overcome AML
Roman Shapiro Dana-Farber Cancer Institute, Boston, MA, United States
Novel CAR targets and strategies for the treatment of acute myeloid leukemia (AML)
Tim Sauer Heidelberg University Hospital, Heidelberg, Germany
T-cell engagers in lymphoma
The emerging role of mosunetuzumab as frontline therapy of follicular lymphoma
Lorenzo Falchi Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Epcoritamab: current data and ongoing trials in lymphoid malignancies
Alexey Danilov City of Hope, Duarte, CA, United States
Bispecific antibodies and chemotherapy in LBCL: Is frontline therapy inevitable?
Jason Westin The University of Texas MD Anderson Cancer Center, Houston, TX, United States
TBC
CARs in lymphoma
NK cell based cellular therapies for B-cell lymphoma
Paolo Strati The University of Texas MD Anderson Cancer Center, Houston, TX, United States
CD5 CAR for T cell lymphoma
Marco Ruella University of Pennsylvania, Philadelphia, PA, United States
TBC
Off-the-shelf, CRISPR-edited anti-CD19 CAR-T: vispa-cel (CB-010)
Stephen Schuster Perelman School of Medicine, Philadelphia, PA, United States
TBC
In vivo CARs in lymphoma and myeloma
Keynote: the lymphoma microenvironment and resistance to CAR T-cell therapy
Michael Green MD Anderson Cancer Center, Houston, TX, United States
In vivo CAR T for hematologic malignancies
Saar Gill Perelman School of Medicine, Philadelphia, PA, United States
UB-VV111 for CD19+ B-cell malignancies
Michael Bishop University of Chicago Medical Center, Chicago, IL, United States
ESO‑T01 for R/R multiple myeloma
Heng Mei Huazhong University of Science and Technology, Wuhan, China
Taking MMyCAR to the bodyshop
Simon Harrison Peter MacCallum Cancer Centre, Melbourne, Australia
Navigating the broader challenges in CAR T-cell therapy
Non-relapse mortality and long-term risks of CAR T-cell therapy
Kai Rejeski LMU Munich, Munich, Germany
CAR T or BsAb: Relative values
Krish Patel Sarah Cannon Research Institute, Nashville, TN, United States
Climbing the CAR T mountain in the community
Tara Graff Misson Cancer and Blood, Waukee, IA, United States
Dual-targeting CARs in lymphoma
CD19/CD20 dual targeting CAR T in 2L+ DLBCL: Key data from Prizlo-cel (formerly JNJ-4496)
Krish Patel Sarah Cannon Research Institute, Nashville, TN, United States
Dual-antigen CAR T-cells with bicistronic design and rapid manufacturing with KITE 363/KITE 753 for lymphoma
Saurabh Dahiya Stanford Medicine, Stanford, CA, United States
TBC
Ronde-cel, a CD62L enriched CD19/CD20 CAR T-cell candidate, achieves robust expansion, high rates of durable complete response and retains a memory phenotype post-Infusion in patients with LBCL
Akil Merchant Cedars-Sinai Medical Center, Los Angeles, CA, United States
High CR rates with durable responses in high-risk MCL with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time (ATALANTA-1 MCL cohort)
Marie Kersten Amsterdam UMC, Amsterdam, Netherlands
Translational advances in multiple myeloma
Myeloma intrinsic mechanisms of resistance to T-cell redirected therapies
Francesco Maura Memorial Sloan Kettering Cancer Center, New York, NY, United States
Coming Soon
Antigen escape and mechanisms of resistance to bispecific T cell engagers
Holly Lee University of Calgary's Cumming School of Medicine, Calgary, Canada
TBC
T-cell engagers & CARs for multiple myeloma
MajesTEC-3 and teclistamab/talquetamab combinations in earlier lines
Paula Rodríguez-Otero University of Navarra, Navarra, Spain
Trispecific antibodies for myeloma – the new way forward?
Rakesh Popat University College London Hospitals NHS Foundation Trust, London, United Kingdom
ImmunoPLANT immune consolidation in newly diagnosed multiple myeloma
Dickran Kazandjian Sylvester Comprehensive Cancer Center, Miami, FL, United States
Sequential CAR T cell and bispecific antibody therapy for myeloma
Adam Cohen University of Pennsylvania, Philadelphia, PA, United States
CARs for multiple myeloma
KarMMa-3: Ide-cel outcomes in triple-class-exposed multiple myeloma
Doris Hansen Moffitt Cancer Center, Tampa, FL, United States
Cilta-cel updates from CARTITUDE 4 and beyond
Rakesh Popat University College London Hospitals NHS Foundation Trust, London, United Kingdom
Translating anito-cel into the clinic: Emerging data and future directions
Ciara Freeman Moffitt Cancer Center, Tampa, FL, United States
TBC
CB-011, an allogeneic anti-BCMA CAR-T cell therapy with immune cloaking, in patients with R/R MM
Adriana Rossi Mount Sinai School of Medicine, New York City, NY, United States
GPRC5D-targeted CAR T-cell therapy for multiple myeloma
Eric Jurgens Memorial Sloan Kettering Cancer Center, New York, NY, United States
TBC
